Details

Autor(en) / Beteiligte

• Alvarado, Luis
• Sharma, Nishtha
• Lerma, Roxann
• Dwivedi, Alok
• Ahmad, Adeel
• Hechanova, Aimee
• Payan-Schober, Fernanda
• Nwosu, Azikiwe
• Alkhalili, Eyas

Titel

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

Ist Teil von

• World journal of surgery, 2022-04, Vol.46 (4), p.813-819

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Secondary hyperparathyroidism in patients with end stage renal disease on dialysis is associated with bone pain and fractures in addition to cardiovascular morbidity. Cinacalcet is the most commonly used drug to treat such patients, but it has never been compared to surgery. The goal of this study is to compare the long-term outcomes and survival between cinacalcet and parathyroidectomy in the treatment of secondary hyperparathyroidism in hemodialysis patients. Methods Adult patients on hemodialysis who were treated with cinacalcet or parathyroidectomy in the United States Renal Data System were included. Patients treated with surgery ( n  = 2023) were compared using 1:1 propensity score matching ratio to a cohort of patients treated with cinacalcet. A Cox regression analysis was conducted to compare the overall mortality. Results The propensity score matching successfully created two groups with similar demographics. Patients in the surgery group had a higher mean peak PTH level prior to therapy (2066.8 vs 1425.4, P  < 0.001). No difference was observed in the development of new-onset coronary artery disease (7.7% vs 7.9%, P  = 0.8) or cerebrovascular disease (7% vs 6.7%, P  = 0.8). Surgical patients had a higher rate of pathologic fractures (27.8% vs 24.9%, P  = 0.04). Survival analysis showed that patients undergoing surgery had a better 5-year survival (65.6% vs 57.8%) and were less likely to die within the study period (HR 0.77, 95% CI 0.7–0.85, P  < 0.0001). Conclusions Patients on dialysis undergoing parathyroidectomy for the treatment of secondary hyperparathyroidism have a better overall survival than those treated with cinacalcet.